-
A Network Pharmacology-Based Investigation into the Mechanism of Quercetin Combined with Rosuvastatin in Delaying Diabetic Nephropathy via Inhibiting NRK-52E Cell Ferroptosis
06 Aug 2025 09:14 GMT
… Potential Targets of Drugs in Treating DN
The … treatment for patients with impaired kidney function. Eur Rev Med Pharmacol … Prescription cholesterol-lowering medication use in adults aged … . Diabetic nephropathy: pathogenesis to cure. Curr Drug Targets. 2022 …
-
Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress
05 Aug 2025 09:00 GMT
… healthy volunteers demonstrated favorable pharmacokinetic (PK) characteristics
AIC468 … cause BK virus-associated nephropathy (BKVAN), affecting … is no approved antiviral treatment specifically for BKV. … therapies to effectively treat infection. Our flagship …
-
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
05 Aug 2025 06:00 GMT
… in Q4 2025
UK Clinical Trial Application (CTA) approval shortly … on the recent FDA IND clearance and EMA orphan drug designation, this … administration of PS-002 to treat IgAN. In the Phase 1 … the lead asset for treatment of IgA Nephropathy (IgAN) and other …
-
Medical Thawing System Market Research Report & Outlook | CAGR of 11.6%
06 Aug 2025 14:00 GMT
… blood banks, biotechnology & pharmaceutical companies, and research laboratories. … plasma for transfusions and treatments.
Challenges and Opportunities
Despite … alliedmarketresearch.com/diabetic-nephropathy-market-A16604
Telemedicine Market …
-
CDC insists people get MORE COVID shots, despite long list of dangerous side effects
06 Aug 2025 08:30 GMT
… science,” publicly rejected existing treatments that could, and did … diseases such as immunoglobulin nephropathy, neutrophil cytoplasmic autoantibodies, … continuation of Big Pharma’s campaign to … United States Food and Drug Administration Commissioner Dr. …
-
NEFECON(R) receives NMPA approval for production expansion in China
06 Aug 2025 08:01 GMT
Everest Medicines has announced that the supplemental application for the production expansion of NEFECON has been officially approved by China’s National Medical Products Administration (NMPA).
This approval for production expansion will further boost …
-
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
05 Aug 2025 11:00 GMT
… on developing and commercializing transformative treatments for patients with serious immunological … ORIGIN 3 trial of atacicept in patients with IgA Nephropathy (IgAN), … FDA Breakthrough Therapy Designation for the treatment of IgAN, which reflects the FDA …
-
Synergistic Potential of Trikatu Essential Oil as an Aromatherapy Agent: A Chemical and Mechanistic Review
06 Aug 2025 09:15 GMT
… a complementary therapy for treating mental and physical … the prevention and supplemental treatment of anxiety disorders, … B. Zingiberene Attenuates Diabetic Nephropathy Inhibiting Oxidative Stress and … guidelines for clinical trial of herbal drugs. J Pharm …
-
Risk Prediction of Postoperative Renal Dysfunction Based on Preoperative Lipid Profiles in Renal Transplant Recipients: A Retrospective Cohort Study
06 Aug 2025 09:14 GMT
… by the Chronic Nephropathy Epidemiology Collaborative Group … transplanted organ. These drugs, while critical for … informed decisions about treatment strategies, including medication choices.
Conclusion
… analysis of the FAVORIT trial. Am J Hypertens. …
-
Everest Medicines Announces Full Approval of NEFECON® in Taiwan
06 Aug 2025 07:03 GMT
… full confirmatory trial analysis to … . Food and Drug Administration (FDA), the European … and commercializing transformative pharmaceutical products and vaccines … TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY …
About
© 1995-2025